Russo Giuseppina T, Corigliano Gerardo, Arturi Franco, Cavallo Maria Gisella, Bette Cristiano, Mannucci Edoardo
Department of Clinical and Experimental Medicine, "Gaetano Martino" University Hospital, Messina, Italy.
Diabetology Service, Italian Diabetes Association, Napoli, Italy.
Nutr Metab Cardiovasc Dis. 2022 May;32(5):1195-1201. doi: 10.1016/j.numecd.2022.01.026. Epub 2022 Jan 29.
The prevalence of type 2 diabetes (T2D) in Italy is increasing and cardiovascular disease (CVD) represents the leading cause of death in this population. CAPTURE was a multinational, multicentre, non-interventional, cross-sectional study assessing the prevalence of CVD, atherosclerotic CVD (AsCVD) and CVD subtypes among patients with T2D, across 13 countries. Here we report the results from Italy.
Overall, 816 patients with T2D (median age, 69 years [interquartile range: 62-75]; median duration of diabetes, 11.2 years [interquartile range: 5.7-18.7]) were recruited during routine clinical visits at secondary care centres in Italy between December 2018-September 2019. The prevalence of CVD was estimated at 38.8%, largely accounted for by AsCVD (33.1%). The most prevalent CVD subtype was coronary heart disease (20.8%), followed by carotid artery disease (13.2%). Most patients (85.9%) were prescribed oral glucose-lowering agents (GLAs), particularly biguanide (76.7%). Insulin use was higher in patients with CVD (41.3%) than in patients without CVD (32.9%). Sodium-glucose co-transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were prescribed to 20.2% vs 14.6%, and 14.5% vs 16.6% of patients with CVD compared to those without CVD, respectively.
The results show that, in Italy, more than one in three patients with T2D attending secondary care centres have CVD, 85% of whom have AsCVD, yet only a minority are treated with SGLT2is and GLP-1 RAs, in discordance with the recommendations of current national and international guidelines.
意大利2型糖尿病（T2D）的患病率正在上升，心血管疾病（CVD）是该人群的主要死因。CAPTURE是一项跨国、多中心、非干预性横断面研究，评估了13个国家T2D患者中CVD、动脉粥样硬化性心血管疾病（AsCVD）及CVD亚型的患病率。在此，我们报告意大利的研究结果。
2018年12月至2019年9月期间，在意大利二级保健中心的常规临床就诊中，共招募了816例T2D患者（中位年龄69岁[四分位间距：62 - 75岁]；糖尿病中位病程11.2年[四分位间距：5.7 - 18.7年]）。CVD的患病率估计为38.8%，主要由AsCVD（33.1%）构成。最常见的CVD亚型是冠心病（20.8%），其次是颈动脉疾病（13.2%）。大多数患者（85.9%）接受了口服降糖药（GLA）治疗，尤其是双胍类药物（76.7%）。CVD患者中胰岛素的使用比例（41.3%）高于无CVD患者（32.9%）。与无CVD的患者相比，CVD患者中分别有20.2%和14.6%、14.5%和16.6%的患者使用了钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）和胰高血糖素样肽-1受体激动剂（GLP-1 RA）。
结果显示，在意大利，在二级保健中心就诊的T2D患者中，超过三分之一患有CVD，其中85%患有AsCVD，但只有少数患者接受SGLT2i和GLP-1 RA治疗，这与当前国家和国际指南的建议不一致。
